<!doctype html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">

    <!-- Bootstrap CSS -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@100;200;300;400;500;600;700;800;900&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <link rel="stylesheet" href="css/style.css">

    <title>Agios</title>
  </head>
  <body>
    <nav class="navbar navbar-expand-lg navbar-dark">
      <div class="container">
        <a class="navbar-brand" href="index.html">
          <img src="images/logo.png" />
        </a>

        <ul class="navbar-nav ml-auto">
            <li class="nav-item active">
              <a class="nav-link" href="index.html">
                <img src="images/icons/home-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="peak-registry.html">
                <img src="images/icons/peak-registry-icon.png" width="30">
              </a>
            </li>
            <li class="nav-item active">
              <a class="nav-link" href="pkr-activator-pipeline.html">
                <img src="images/icons/pipeline-icon.png" width="30">
              </a>
            </li>
          </ul>
      </div>
    </nav>
    <main class="pipeline-details">
      <div class="container">
        <div class="row">
          <div class="col-sm-9 col-7">
            <h1 class="mb-4">DRIVE-PK</h1>
          </div>
          <div class="col-sm-3 col-5">
            <span class="badge blue-dark float-right mt-1">STATUS: CORE STUDY COMPLETED</span>
          </div>

          <div class="col-md-8">
            <h4 class="font-weight-normal mb-3">First-in-patients, open-label phase 2 study evaluating the safety and efficacy of mitapivat in adults with PK deficiency who do not receive regular transfusions</h4>
            
            <div class="block">
              <div class="row">
                <div class="col-lg-12 d-flex align-items-center">
                  <img src="images/drive-pk-study-design.png" class="mb-0" />
                </div>
              </div>
            </div>

            <div class="row">     
                <div class="col-lg-12">
                  <ul class="mb-4 pl-20">
                    <li>Treatment with mitapivat was associated with a rapid, clinically significant increase of >1 g/dL hemoglobin in 50% of treated patients:
                        <ul class="pl-20">
                          <li>Hemoglobin response was sustained for up to 35 months with ongoing treatment and was associated with improvements in markers of hemolysis</li>
                          <li>Hemoglobin responses were observed in patients with diverse PKLR genotypes, all of whom had at lease one missense mutation</li>
                        </ul>
                       </li>
                       <li>The most common adverse events occurred at drug initiation and were transient (headache, insomnia, and nausea):
                          <ul class="pl-20">
                            <li>Grade 3 or greater adverse events that were considered by the investigator to be drug related were seen in 17% of patients treated daily for up to 35 months</li>
                          </ul>
                       </li>
                       <li>This study supports the potential of mitapivat as an investigational long-term disease-modifying therapy for PK deficiency</li>
                       <li>This study supports the potential of mitapivat as an investigational long-term disease-modifying therapy for PK deficiency</li>
                  </ul>
                </div>
            </div>
          </div>

          <div class="col-md-4">
              <div class="block side-block-container">
                <div class="side-block">
                  <p class="mb-1"><strong>Primary Objective</strong></p>
                  <p class="mb-0">Assess the safety and tolerability of mitapivat administration in patients with PK deficiency</p>
                </div>
                <div class="side-block side-block-gray">
                  <p class="mb-1"><strong>Secondary Objectives</strong></p>
                  <p class="mb-0">PK/PD profile of mitapivat; clinical efficacy as measured by changes in hemoglobin and markers of hemolysis</p>
                </div>
                <div class="side-block">
                  <p class="mb-1"><strong>Key Eligibility Criteria</strong></p>
                  <ul class="mb-0 pl-20">
                      <li>≥18 years of age</li>
                      <li>Documented diagnosis of PK deficiency confirmed by PKLR genotyping</li>
                      <li>Hemoglobin levels ≤12.0 g/dL (males) or ≤11.0 g/dL (females)</li>
                      <li>No transfusions in the past 4 months with no more than 3 units of red blood cells in the previous 12 months</li>
                  </ul>
                </div>
              </div>
            </div>

        </div>
        <footer>
            <div class="row">
              <div class="col-md-7">
                <p class="text-left mb-4">‘Drive-PK’ and study schema not included in manuscript.<br/>
                All patients provided written informed consent<br/> 
                <sup>a</sup>Dose adjustments were allowed in the core period on the basis of safety, side-effect profile, and hemoglobin response <br/>
                <sup>b</sup>Protocol amendments required that patients who did not have an increase from baseline hemoglobin of ≥1.0 g/dL for ≥3 of prior 4 measurements withdraw from the study; and that patients treated with mitapivat doses >25 mg BID undergo a dose taper and continue on a dose that maintained their hemoglobin level at no lower than 1.0 g/dL below their pre-taper hemoglobin level<br/>
                BID = twice daily, PK/PD = pharmacokinetic/pharmacodynamics<br/>
                <strong>Full results published in Grace RF et al. NEJM 2019; 381:933-44.</strong></p>
              </div>
              <div class="col-md-5">
                <p class="text-right">EudraCT 2015-000484-13<br/>
                For full inclusion and exclusion criteria, as well as study 
                locations, search ClinicalTrials.gov for (NCT02476916)<br/>
                For more information (physician/HCP only), please email medinfo@agios.com<br/>
                &copy;2021 Agios Pharmaceuticals, Inc. All rights reserved.</p>
              </div>
            </div>
        </footer>
      </div>
    </main>


    <!-- Optional JavaScript -->
    <!-- jQuery first, then Popper.js, then Bootstrap JS -->
    <!-- <script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.12.9/umd/popper.min.js" integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q" crossorigin="anonymous"></script> -->
    <script src="js/jquery-3.4.1.min.js"></script>
    <script src="js/bootstrap.min.js"></script>
  </body>
</html>